Metropolitan Life Insurance CO Immunovant, Inc. Transaction History

Metropolitan Life Insurance CO

$281 Million
Q3 2024

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$30.27 - $43.79 $4,934 - $7,137	-163 Reduced 5.23%	2,955 $95,000
Q3 2023 Nov 14, 2023	BUY	$18.55 - $39.96 $3,097 - $6,673	167 Added 5.66%	3,118 $119,000
Q2 2023 Aug 10, 2023	BUY	$14.2 - $23.75 $8,307 - $13,893	585 Added 24.73%	2,951 $55,000
Q1 2023 May 15, 2023	SELL	$15.27 - $19.72 $5,924 - $7,651	-388 Reduced 14.09%	2,366 $36,000
Q4 2022 Jun 14, 2023	BUY	$6.59 - $17.75 $2,556 - $6,887	388 Added 16.4%	2,754 $48.9 Million
Q4 2022 Mar 30, 2023	BUY	$6.59 - $17.75 $1,970 - $5,307	299 Added 12.18%	2,754 $48,000
Q4 2022 Feb 15, 2023	BUY	$6.59 - $17.75 $1,970 - $5,307	299 Added 12.18%	2,754 $48,000
Q3 2022 Jun 14, 2023	BUY	$3.93 - $6.37 $349 - $566	89 Added 3.76%	2,455 $13.7 Million
Q3 2022 Mar 30, 2023	SELL	$3.93 - $6.37 $1,190 - $1,930	-303 Reduced 10.99%	2,455 $13,000
Q3 2022 Nov 14, 2022	BUY	$3.93 - $6.37 $9,648 - $15,638	2,455 New	2,455 $14,000
Q2 2022 Aug 11, 2022	SELL	$3.38 - $5.65 $9,322 - $15,582	-2,758 Closed	0 $0
Q1 2022 Jun 20, 2023	BUY	$5.06 - $8.77 $1,983 - $3,437	392 Added 16.57%	2,758 $15,000
Q1 2022 Mar 30, 2023	SELL	$5.06 - $8.77 $6,264 - $10,857	-1,238 Reduced 30.98%	2,758 $15,000
Q1 2022 May 12, 2022	SELL	$5.06 - $8.77 $6,264 - $10,857	-1,238 Reduced 30.98%	2,758 $15,000
Q4 2021 Jun 21, 2023	BUY	$7.33 - $9.32 $11,947 - $15,191	1,630 Added 68.89%	3,996 $34,000
Q4 2021 Mar 30, 2023	SELL	$7.33 - $9.32 $10,327 - $13,131	-1,409 Reduced 26.07%	3,996 $34,000
Q4 2021 Feb 15, 2022	SELL	$7.33 - $9.32 $10,327 - $13,131	-1,409 Reduced 26.07%	3,996 $34,000
Q3 2021 Jun 21, 2023	BUY	$7.01 - $11.37 $21,303 - $34,553	3,039 Added 128.44%	5,405 $46,000
Q3 2021 Mar 30, 2023	SELL	$7.01 - $11.37 $47,948 - $77,770	-6,840 Reduced 55.86%	5,405 $46,000
Q3 2021 Nov 15, 2021	SELL	$7.01 - $11.37 $47,948 - $77,770	-6,840 Reduced 55.86%	5,405 $47,000
Q2 2021 Jun 21, 2023	BUY	$9.4 - $16.85 $92,862 - $166,461	9,879 Added 417.54%	12,245 $129,000
Q2 2021 Mar 30, 2023	BUY	$9.4 - $16.85 $27,119 - $48,612	2,885 Added 30.82%	12,245 $129,000
Q2 2021 Aug 16, 2021	BUY	$9.4 - $16.85 $115,018 - $206,176	12,236 Added 135955.56%	12,245 $129,000
Q1 2021 Jun 26, 2023	BUY	$13.08 - $49.6 $91,481 - $346,902	6,994 Added 295.6%	9,360 $150 Million
Q1 2021 Mar 30, 2023	SELL	$13.08 - $49.6 $12,334 - $46,772	-943 Reduced 9.15%	9,360 $150,000
Q1 2021 May 14, 2021	SELL	$13.08 - $49.6 $134,645 - $510,582	-10,294 Reduced 99.91%	9 $150,000
Q4 2020 Jun 22, 2023	BUY	$36.36 - $52.71 $288,589 - $418,359	7,937 Added 335.46%	10,303 $475,000
Q3 2020 Jun 26, 2023	BUY	$22.61 - $38.9 $179,455 - $308,749	7,937 Added 335.46%	10,303 $362,000
Q3 2020 Mar 30, 2023	BUY	$22.61 - $38.9 $85,443 - $147,003	3,779 Added 57.92%	10,303 $362,000
Q3 2020 Nov 13, 2020	BUY	$22.61 - $38.9 $85,443 - $147,003	3,779 Added 57.92%	10,303 $363,000
Q2 2020 Jun 26, 2023	BUY	$13.87 - $28.44 $57,671 - $118,253	4,158 Added 175.74%	6,524 $158,000
Q2 2020 Mar 30, 2023	BUY	$13.87 - $28.44 $52,289 - $107,218	3,770 Added 136.89%	6,524 $158,000
Q2 2020 Aug 14, 2020	BUY	$13.87 - $28.44 $90,487 - $185,542	6,524 New	6,524 $159,000

Others Institutions Holding IMVT

# of Institutions

211

Shares Held

66M

Call Options Held

2.3M

Put Options Held

631K

Vanguard Group Inc Valley Forge, PA

6.66M
Shares

$183 Million
0.0% of portfolio
Black Rock Inc. New York, NY

4.92M
Shares

$135 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

4.35M
Shares

$120 Million
4.41% of portfolio
Armistice Capital, LLC New York, NY

3.55M
Shares

$97.6 Million
1.62% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

3.33M
Shares

$91.6 Million
0.06% of portfolio

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account